Abstract:Proc Amer Assoc Cancer Res, Volume 46, 2005 6067 Ulcerative colitis (UC) is associated with an increased risk of colorectal cancer (CRC), which evolves from dysplasia. Although the molecular events required for UC associated CRC formation remain to be established, recent data suggest that this pathway differs from that of sporadic CRC. In particular, mutation of the p53 gene appears to be an early event in UC associated CRC as is evident from the presence of mutant p53 in non-neoplastic inflamed colonic mucosa. In addition, 70-80% of UC associated CRCs possess mutant p53 while only 27% have APC mutations. However, there are no mouse models that recapitulate the genetic and histopathological changes seen in human UC associated CRC. The dextran sulfate sodium (DSS) model of induced colitis provides a unique opportunity to evaluate the spectrum of histological changes that lead to the development of UC and subsequent dysplasia and CRC similar to UC in humans. To determine the function of p53 in UC associated dysplasia/cancers, p53 wild-type and deficient (p53+/− and p53-/-) mice were treated with 3 cycles of DSS, with each cycle consisting of 4% DSS in the drinking water for 4 days followed by 17 days of untreated water. Animals were allowed to live an additional 120 days on untreated water. At the end of the experiment, tissues were evaluated histopathologically and colon tumor incidence was determined. The tumor incidence in DSS-treated p53-/-, p53+/− and p53+/+ mice was 62%, 19% and 19%, respectively. Tumors were classified pathologically as dysplasia (flat or polypoid, low or high grade) or cancer (defined as invasion of cancer cells into the submucosa or beyond, flat or polypoid). Several important pathological features were observed in these mice. First, colon cancers were found in DSS-treated p53+/− and p53-/- mice, but not in p53+/+ mice. Second, DSS-treated p53+/− mice exhibited predominantly polypoid colonic dysplasia/cancers (polypoid vs. flat, 91% vs. 9%, respectively). In contrast, DSS-treated p53-/- mice exhibited predominantly flat dysplasia/cancers (flat vs. polypoid, 77% vs. 23%, respectively). Third, 29% of the colon cancers identified in p53+/− and p53-/- mice displayed mucinous differentiation, a common characteristic of human UC associated CRC. Fourth, in DSS-treated p53+/− and p53-/- mice, non-neoplastic epithelium and pools of mucin were found in the deeper layers of the bowel wall, similar to human colitis cystica profunda. Although the use of DSS-treated p53 deficient mice as a model for human UC associated CRC has been reported previously by Fujii et al. (2004), we report a much higher incidence of invasive CRC and additional relevant unique features that were not observed in their model. These data indicate that treatment of p53 deficient mice with DSS produces UC associated colorectal dysplasia/cancers with features similar to those of human UC associated CRC. (Supported by NIH R03 CA099122 and an ACS Institutional Research Grant).

Three Years Follow-up on a Colorectal Cancer Screening Program: A Prospective Cohort of 4,961 Asymptomatic Subjects

Su2001 Snail/CXCL-8 Axis Promotes Expression of the Novel Surface Marker CD58 and Self-Renewal of Tumor-Initiating Cells in Colorectal Cancer

A Novel Mouse Model for Colitis-Associated Colon Carcinogenesis Induced by 1,2-Dimethylhydrazine and Dextran Sulfate Sodium

A35 DNA HYPOMETHYLATION INHIBITS TUFT CELL-DERIVED COLITIS-ASSOCIATED CANCER

The Protective Role of Vitamin D3 in Colitis-Associated Colorectal Cancer in a Mouse Model

Sa1993 Claudin-3 Expression Associates With Colonic Epithelial Differentiation and Loss of Its Expression Correlates With Colon Carcinogenesis and Poor Patient Survival

A Purified Membrane Protein from Akkermansia Muciniphila or the Pasteurised Bacterium Blunts Colitis Associated Tumourigenesis by Modulation of CD8+ T Cells in Mice

A study on DH-1/Notch signal transduction pathway in colorectal cancer

Unique Histopathological Features of Dextran Sulfate Sodium-Induced Colonic Lesions in P53 Deficient Mice

A27 DNA HYPOMETHYLATION INDUCED BY 5-AZA-CDR OR LOSS OF DNMT1 INHIBITS COLITIS-ASSOCIATED COLORECTAL CANCER

Colocalization of β-catenin with Notch intracellular domain in colon cancer: a possible role of Notch1 signaling in activation of CyclinD1-mediated cell proliferation

A Nucleotide Analog Prevents Colitis-Associated Cancer via Beta-Catenin Independently of Inflammation and Autophagy

Abstract CN13-05: A Novel Approach for Colorectal Cancer Chemoprevention by Targeting APC-deficient Cells for Apoptosis

Alpha-1 Antitrypsin Inhibits Tumorigenesis and Progression of Colitis-Associated Colon Cancer through Suppression of Inflammatory Neutrophil-Activated Serine Proteases and IGFBP-3 Proteolysis

W1170 Endoscopic Three-Dimensional Optical Coherence Tomography Assessment of Radiofrequency Ablation of Barrett's Esophagus

An ultralow dose of the NADPH oxidase inhibitor diphenyleneiodonium (DPI) is an economical and effective therapeutic agent for the treatment of colitis-associated colorectal cancer

Tropomyosin 2 Regulates Tumor Cell Proliferation, Immune Suppression, and Activation of the JNK Signaling Pathway in Colitis-Associated Cancer (CAC)

Abstract B81: Colorectal Cancer Chemoprevention by Targeting APC-deficient Cells for Apoptosis

872 Mir-650: A Potential Prognostic Biomarker and Therapeutic Target in Non-Metastasis Colorectal Carcinoma

[Alterations of P53 Gene and Microsatellite Instability in Ulcerative Colitis and Ulcerative Colitis-Associated Colorectal Cancer].